ProQR Therapeutics N.V. buy Citigroup Inc.
Start price
19.04.24
/
50%
€1.78
Target price
19.04.25
€1.88
Performance (%)
-36.85%
End price
20.04.25
€1.12
Summary
This prediction ended on 20.04.25 with a price of €1.12. Massive losses of -36.85% were the result for the BUY prediction by Citigroup_Inc_. Citigroup_Inc_ has a follow-up prediction for ProQR Therapeutics N.V. where he still thinks ProQR Therapeutics N.V. is a Buy. Citigroup_Inc_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| ProQR Therapeutics N.V. | -6.074% | -6.074% | -28.100% |
| iShares Core DAX® | 1.732% | 4.638% | 21.634% |
| iShares Nasdaq 100 | 3.304% | 0.517% | 5.422% |
| iShares Nikkei 225® | 2.342% | 0.972% | 15.333% |
| iShares S&P 500 | 2.357% | 0.872% | 3.125% |
Comments by Citigroup_Inc_ for this prediction
In the thread ProQR Therapeutics N.V. diskutieren
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.
Ratings data for PRQR provided by MarketBeat
In the thread Trading ProQR Therapeutics N.V.
Die von Citigroup_Inc_ gewählte maximale Laufzeit wurde überschritten
Current prediction by Citigroup_Inc_ for ProQR Therapeutics N.V.
ProQR Therapeutics N.V.
Start price
Target price
Perf. (%)
€1.87
10.03.25
10.03.25
€3.68
10.03.26
10.03.26
0.11%
23.12.25
23.12.25
